{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:03:00Z","timestamp":1788973380763,"version":"build-2803163510"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>A highly sensitive and versatile liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS) method was developed for the simultaneous quantification of upadacitinib and atorvastatin in rat plasma. The analytes and internal standard were extracted from 30 \u03bcL rat plasma using a simple protein precipitation technique. The method demonstrated excellent linearity over the concentration ranges of 0.5\u2013500\u2009ng\/mL for upadacitinib and 0.05\u2013100\u2009ng\/mL for atorvastatin and precision over all quality control levels. Detection was achieved using multiple reaction monitoring (MRM) in positive ionization mode. Method validation was carried out in accordance with the current ICH M10 guidance on bioanalytical method validation. The validated method was successfully applied to a pharmacokinetic study of a 10 mg oral formulation of upadacitinib and atorvastatin in rats. The pharmacokinetic results confirmed the applicability of the method for the reliable and simultaneous determination of both analytes in rat plasma.<\/jats:p>","DOI":"10.1002\/bmc.70288","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T14:06:11Z","timestamp":1765461971000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Highly Sensitive and Selective Liquid Chromatography\u2013Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3636-2065","authenticated-orcid":false,"given":"Vipul","family":"Joshi","sequence":"first","affiliation":[{"name":"Department of Pharmacokinetics Zydus Research Center  Ahmedabad Gujarat India"},{"name":"Gujarat Technological University  Ahmedabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Vaghela","sequence":"additional","affiliation":[{"name":"A. R. College of Pharmacy  Vallabh Vidyanagar Gujarat India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmal","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics Zydus Research Center  Ahmedabad Gujarat India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Saini","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics Zydus Research Center  Ahmedabad Gujarat India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Giri","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics Zydus Research Center  Ahmedabad Gujarat India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"AbbVie.2022 March 16. \u201cRINVOQ (Upadacitinib) Receives FDA Approval for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis.\u201d AbbVie News. Retrieved May 2 2022 fromhttps:\/\/news.abbvie.com\/news\/press\u2010releases\/rinvoq\u2010upadacitinib\u2010receives\u2010fda\u2010approval\u2010for\u2010treatment\u2010adults\u2010with\u2010moderately\u2010to\u2010severely\u2010active\u2010ulcerative\u2010colitis.htm."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2014.05.011"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2018.12.018"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.10.045"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000406"},{"key":"e_1_2_11_7_1","unstructured":"ICH of Technical Requirements for Pharmaceuticals for Human Use.2022. \u201cICH Harmonised Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis: Step 4 (ICH M10).\u201dhttps:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.47750\/pnr.2022.13.02.016"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.02.003"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2021.123076"},{"key":"e_1_2_11_11_1","unstructured":"National Center for Biotechnology Information. n.d.. \u201cAtorvastatin [PubChem Compound Summary for CID 60823].\u201d InPubChem. Retrieved May 3 2022 fromhttps:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Atorvastatin."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1039\/C7AY00185A"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2013.09.007"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2012.09.002"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.06.062"},{"key":"e_1_2_11_16_1","unstructured":"U.S. Food and Drug Administration.2018. \u201cBioanalytical Method Validation: Guidance for Industry.\u201d U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Researchhttps:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical\u2010Method\u2010Validation\u2010Guidance\u2010for\u2010Industry.pdf."},{"key":"e_1_2_11_17_1","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research.2019. \u201cHighlights of Prescribing Information: RINVOQ (Upadacitinib) Extended\u2010Release Tablets [Prescribing Information].\u201d Retrieved May 2 2022 fromhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211675s000lbl.pdf."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/22297928.2019.1649188"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S332282"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T15:49:27Z","timestamp":1766072967000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.70288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/bmc.70288"],"URL":"https:\/\/doi.org\/10.1002\/bmc.70288","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"2025-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70288"}}